Physician profile
Annu Mohan
NPI 1992751663
$8,062.15
in general payments reported to CMS, 2019-2025
43 companies · $693 in 2025
The $693 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $748 · 2020: $689 · 2021: $1,207 · 2022: $1,426 · 2023: $2,206 · 2024: $1,094 · 2025: $693.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,993.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,992.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,005.67 | 2021-2025 | |
| Merz North America, INC. | $969.43 | 2019-2023 | Xeomin |
| Novo Nordisk INC | $773.59 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $615.09 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Pfizer INC. | $482.58 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $363.76 | 2019-2025 | Spravato |
| Astellas Pharma US INC | $360.21 | 2019-2025 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $284.29 | 2021-2024 | |
| Xeris Pharmaceuticals, INC. | $249.27 | 2021-2024 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $234.66 | 2019-2023 | Ofev, Jardiance |
| Astrazeneca Pharmaceuticals LP | $224.08 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Otsuka America Pharmaceutical, INC. | $211.62 | 2022-2025 | Rexulti |
| Corium, LLC | $211.60 | 2022-2025 | Azstarys |
| Sanofi-Aventis U.S. LLC | $184.94 | 2019-2022 | |
| Amgen INC. | $184.72 | 2020-2025 | Otezla, Repatha, Evenity |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $151.12 | 2019-2023 | Verquvo, Januvia, Belsomra |
| Axsome Therapeutics, INC. | $150.91 | 2023-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $127.18 | 2019-2025 | Ingrezza, Ongentys |
| Takeda Pharmaceuticals U.S.A., INC. | $120.94 | 2019-2022 | |
| Glaxosmithkline, LLC. | $115.86 | 2021-2024 | Trelegy Ellipta, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $113.96 | 2019-2025 | |
| Abbott Laboratories | $83.65 | 2021-2024 | Freestyle Libre 3 |
| Dexcom, INC. | $83.31 | 2021-2023 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $81.57 | 2022-2025 | Caplyta |
| Exact Sciences Corporation | $76.76 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amarin Pharma, INC. | $70.41 | 2021-2022 | |
| Esperion Therapeutics, INC. | $65.58 | 2020-2025 | Nexletol |
| Biohaven Pharmaceutical Holding Company LTD. | $65.09 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $54.55 | 2019-2023 | Camzyos, Eliquis |
| Kowa Pharmaceuticals America, INC. | $51.02 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.94 | 2022-2023 | Xifaxan |
| Fidia Pharma USA INC. | $36.64 | 2020-2021 | |
| Eisai INC. | $32.85 | 2021-2022 | |
| Medtronic, INC. | $30.08 | 2025 | Linq II |
| Genentech USA, INC. | $23.24 | 2021 | |
| Hologic Sales and Service, LLC | $18.95 | 2024 | Aptima, Thinprep 2000 Processor |
| Daiichi Sankyo INC. | $18.80 | 2022 | |
| Baxter Healthcare | $16.16 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Bardy Diagnostics, INC. | $15.34 | 2021 | |
| Mylan Specialty L.P. | $14.80 | 2020 | |
| Allergan, INC. | $12.97 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $12.64 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $12.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Annu Mohan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.